

Certificate No. SHR/738/GBSL/2014 – 2015


**CERTIFICATE**

The  
Board of Directors  
Gufic Biosciences Limited  
Mumbai

1. We have reviewed the accompanying statement of unaudited financial results of **GUFIC BIOSCIENCES LIMITED** for the period ended **December 31, 2014** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. *Attention is invited to:*
  - a. *The company introduced implementation of ERP system in F.Y. 2013 – 14 in stages and only certain modules are operational, accuracy of which are yet to be tested. The unaudited financial amounts for quarter December 31, 2014 has been compiled from various sources by the management, including introduced ERP Modules. We have relied on management representation that it has taken enough care and diligence to ensure that the presented data and accounts, so compiled, are true & correct.*
  - b. *We are unable to express our opinion on the recoverability of certain debts, aggregating to Rs. 271.61 lacs, which continue to be outstanding for more than one year and of certain loans and advances of Rs. 31.92 lacs which are outstanding for more than two year. However, in the opinion of the management, the same are good and recoverable and thus no provision is required in respect thereof.*
  - c. *In the absence of information, we have relied upon the segment wise report prepared by the management based on the nature of product, risk and returns, organization structure. The figures have been regrouped and reclassified wherever necessary by the management.*

4. Based on our review conducted as above and ***subject to our comments in para 3 above***, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the Accounting Standards notified under section 133 of the Companies Act, 2013 read with Rule 7 of Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S H R & CO**  
**Chartered Accountant**  
**FRN: 120491W**



**Deep N Shroff**  
**Partner**


M. No: 122592


Mumbai dated February 13, 2015

GUFIC BIOSCIENCES LIMITED						
Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069						
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2014						
Particulars	Rs. In Lacs					
	Quarter Ended 31.12.2014 Unaudited	Quarter Ended 30.09.2014 Unaudited	Quarter Ended 31.12.2013 Unaudited	For the Period Ended 31.12.2014 Unaudited	For the Period Ended 31.12.2013 Unaudited	For the Year Ended 31.03.2014 Audited
<b>INCOME:</b>						
Net Sales / Income from Operations (Net of Excise Duty)	3423.19	4263.81	3130.89	11595.05	8569.25	12291.58
Other Operating Income	10.99	12.58	4.84	25.62	9.06	22.92
<b>Total Income from Operations (Net)</b>	<b>3434.18</b>	<b>4276.39</b>	<b>3135.73</b>	<b>11620.68</b>	<b>8578.31</b>	<b>12314.50</b>
<b>EXPENSES:</b>						
Cost of Materials Consumed	1536.51	2262.43	1299.25	5445.88	3652.46	5194.33
Purchase of Stock-in-Trade	372.16	272.73	433.18	1198.33	903.68	1377.03
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(229.61)	(48.91)	(325.58)	(280.17)	(103.61)	40.87
Employee Benefits Expenses	460.44	457.80	433.09	1285.77	826.25	1194.34
Depreciation and Amortisation Expenses	105.57	103.11	61.38	307.92	182.14	246.77
Other Expenses	950.54	907.55	986.40	2807.99	2414.09	3291.42
<b>Total Expenses</b>	<b>3195.61</b>	<b>3954.71</b>	<b>2887.72</b>	<b>10765.72</b>	<b>7875.01</b>	<b>11344.75</b>
<b>Profit from Operations before Other Income, finance costs and Exceptional Items</b>	<b>238.56</b>	<b>321.69</b>	<b>248.01</b>	<b>854.96</b>	<b>703.30</b>	<b>969.75</b>
Other Income	(1.46)	(11.88)	7.72	15.90	14.95	49.15
<b>Profit from ordinary activities before finance costs and exceptional items</b>	<b>237.10</b>	<b>309.81</b>	<b>255.73</b>	<b>870.86</b>	<b>718.24</b>	<b>1018.90</b>
Finance Costs	101.42	110.94	100.16	318.21	289.54	391.57
<b>Profit from ordinary activities after finance costs but before exceptional items</b>	<b>135.68</b>	<b>198.87</b>	<b>155.58</b>	<b>552.65</b>	<b>428.71</b>	<b>627.32</b>
Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
<b>Profit from Ordinary Activities Before Tax</b>	<b>135.68</b>	<b>198.87</b>	<b>155.58</b>	<b>552.65</b>	<b>428.71</b>	<b>627.32</b>
Current Tax	81.50	103.61	42.50	260.11	109.07	151.00
Deferred Tax	(12.79)	(27.65)	6.45	(16.71)	18.71	7.01
Short/(Excess) Tax Provisions of Earlier Years	(0.69)	4.43	0.00	3.75	0.00	42.90
<b>Net Profit from Ordinary Activities After Tax</b>	<b>67.66</b>	<b>118.47</b>	<b>106.63</b>	<b>305.50</b>	<b>300.93</b>	<b>426.41</b>
Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00	0.00
<b>Net Profit for the Period</b>	<b>67.66</b>	<b>118.47</b>	<b>106.63</b>	<b>305.50</b>	<b>300.93</b>	<b>426.41</b>
Paid up Equity Share Capital (Face Value of Rs 1 /- Each)	773.50	773.50	773.50	773.50	773.50	773.50
Reserves Excluding Revaluation Reserves	1864.57	1796.92	1766.82	1864.57	1766.82	1847.35
<b>E.P.S</b>	<b>0.09</b>	<b>0.15</b>	<b>0.14</b>	<b>0.39</b>	<b>0.39</b>	<b>0.55</b>
<b>Public Shareholding</b>						
-- Number of Shares of Rs 1 /- Each	23222355	23222355	23222355	23222355	23222355	23222355
-- Percentage of shareholding	30.02%	30.02%	30.02%	30.02%	30.02%	30.02%
<b>Promoters and Promoter group Shareholding</b>						
<b>a) Pledged / Encumbered</b>						
-- Number of Shares of Rs 1 /- Each	0	0	0	0	0	0
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
-- Percentage of Shareholding on total Capital of the company	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
<b>b) Non - Encumbered</b>						
-- Number of Shares of Rs 1 /- Each	54127645	54127645	54127645	54127645	54127645	54127645
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
-- Percentage of Shareholding on total Capital of the company	69.98%	69.98%	69.98%	69.98%	69.98%	69.98%

The above Results were reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 13th February, 2015. The Financial Results have been Audited by the Statutory Auditor of the Company

Place: Mumbai  
Date: 13.02.2015

For GUFIC BIOSCIENCES LTD.  
  
Jayesh A Choksi  
Managing Director



**GUFIC BIOSCIENCES LIMITED**

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

**UNAUDITED SEGMENT WISE RESULTS FOR THE QUARTER ENDED 31.12.2014**

Particulars	Quarter Ended 31.12.2014 Unaudited	Quarter Ended 30.09.2014 Unaudited	Quarter Ended 31.12.2013 Unaudited	For the Period Ended 31.12.2014 Unaudited	For the Period Ended 31.12.2013 Unaudited	For the Period Ended 31.03.2014 Audited
<b>SEGMENT REVENUE</b>						
<b>Sales &amp; Service</b>						
Pharma	3253.27	3900.81	2822.90	10709.05	7666.26	11051.26
Consumer	169.91	363.00	307.99	886.01	902.99	1240.32
<b>Total</b>	<b>3423.19</b>	<b>4263.81</b>	<b>3130.89</b>	<b>11595.05</b>	<b>8569.25</b>	<b>12291.58</b>
Unallocabel Income	9.52	0.70	12.56	41.52	24.00	72.07
<b>Total Segment Revenue</b>	<b>3432.71</b>	<b>4264.51</b>	<b>3143.45</b>	<b>11636.58</b>	<b>8593.25</b>	<b>12363.65</b>
<b>SEGMENT RESULTS</b>						
Pharma	634.39	760.68	545.15	2088.26	1484.23	2144.25
Consumer	17.94	38.32	60.59	93.56	175.69	238.83
<b>TOTAL</b>	<b>652.33</b>	<b>798.99</b>	<b>605.74</b>	<b>2181.83</b>	<b>1659.92</b>	<b>2383.08</b>
Less: Unallocated over heads	309.66	386.07	288.63	1003.05	759.54	1117.41
Finance Charges	101.42	110.94	100.16	318.21	289.54	391.57
Depreciation	105.57	103.11	61.38	307.92	182.14	246.77
Tax provision	68.02	80.40	48.95	247.15	127.78	200.91
<b>Net Profit after Tax</b>	<b>67.66</b>	<b>118.47</b>	<b>106.63</b>	<b>305.50</b>	<b>300.93</b>	<b>426.41</b>

**Notes forming part of the un-audited financial results for the quarter ended December 31, 2014**

The above interim financial results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors in their meetings held on February 13, 2015. The same has been subjected to limited review by the Statutory Auditors.

2. For the preparation of these financial results, the company has followed the same accounting policies and generally accepted practices adopted for the preparation of audited financial statements for the year ended March 31, 2014, except for accounting of depreciation on fixed assets.

3. As per the requirement of the Companies Act, 2013 (Act), the company has reassessed the remaining useful life of the fixed assets taking into consideration the useful life prescribed in Schedule II of the Act. This has resulted in an additional charge of depreciation of Rs. 27.54 Lacs for the quarter ended December 31, 2014 and Rs. 50.24 Lacs for the nine Months ended December 31, 2014. Further, the written down value of the assets of Rs. 288.28 Lacs as on April 1, 2014 (net of deferred tax of Rs. 138.45 Lacs) whose residual life is exhausted has been adjusted against the opening balance of Reserves and Surplus.

3. Disclosure about investor complaints: Complaints at the beginning of the period Nil, Received during the period Nil; Disposed off during the period: Nil, Unresolved as on December 31, 2014: Nil.

4. Corresponding previous period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.

5. The figures of the last quarter of financial year 2013 – 2014 are the balancing figures between audited figures in respect of the full financial year upto March 31 2014 and the unaudited published year – to – date figures upto December 31, 2013 which were subject to limited review.

By Order of the Board  
Gufic Biosciences Limited

Jayesh P. Choksi  
Chairman

Mumbai dated February 13, 2015

